Khusimene is a sesquiterpene hydrocarbon strongly associated with vetiver root oil and related zizaane-type odor chemistry. Public evidence is strongest for identity, biosynthetic relevance, and its role as one of the compounds contributing to characteristic vetiver odor. Direct constituent-level pharmacology is sparse, so khusimene is best described as a vetiver marker constituent and fragrance-relevant precursor rather than as a well-characterized bioactive.
Chemical identity and composition
NIST and PubChem link khusimene with the zizaene naming family, giving formula C15H24 and synonym relationships among khusimene, khusene, and zizaene. In accessible vetiver literature khusimene is repeatedly listed among the compounds that contribute to characteristic vetiver odor, and biosynthetic engineering papers describe (+)-zizaene as a precursor of khusimol. Within the AromaForge archive, public vetiver GC-MS records quantify khusimene as a minor but recurrent constituent.
Aroma and practical use
- Use the recorded woody, dry, earthy, vetiver-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2012 vetiver composition paper stated that khusimene is one of the important compounds that impart the characteristic odor of south Indian vetiver oils.
A 2012 vetiver composition paper stated that khusimene is one of the important compounds that impart the characteristic odor of south Indian vetiver oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2015 biotechnology paper reported that a purified (+)-zizaene synthase catalyzed the production of (+)-zizaene from farnesyl diphosphate and described that product as a precursor of khusimol, supporting khusimene's biosynthetic relevance.
A 2015 biotechnology paper reported that a purified (+)-zizaene synthase catalyzed the production of (+)-zizaene from farnesyl diphosphate and described that product as a precursor of khusimol, supporting khusimene's biosynthetic relevance.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human safety study, IFRA limit, or modern dermal threshold for isolated khusimene was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Publicly accessible information for khusimene is dominated by analytical identity and vetiver composition references rather than by toxicology monographs.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because current evidence is largely odor and chemistry focused, archive copy should avoid implying antioxidant, anti-inflammatory, or other therapeutic effects for isolated khusimene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
sesquiterpene biosynthetic precursor to khusimol
A terpene synthase study reported production of (+)-zizaene, identified as a khusimene synonym in major chemistry databases, from farnesyl diphosphate as a precursor of khusimol.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical studies specific to isolated khusimene were verified in this pass.
- Accessible standalone bioactivity data for khusimene are sparse compared with the broader vetiver-oil literature.
- A transparent constituent-specific dermal, inhalation, or sensitization threshold for isolated khusimene was not located in the reviewed public sources.
- Targeted web searches for an IFRA/Tisserand/EU Annex III dermal limit and sensitization/phototoxicity data specific to khusimene (CAS 18444-94-5) returned no authoritative results (2026-07-13). The previously stored dermal_limit_pct (25) and sensitizing:true had no supporting citation and have been corrected to null/unknown pending real data.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.